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Abstract
Most missense mutations causing Rett syndrome (RTT) affect domains of MeCP2 that have been shown to either bind
methylated DNA or interact with a transcriptional co-repressor complex. Several mutations, however, including the C-termi-
nal truncations that account for 10% of cases, fall outside these characterized domains. We studied the molecular conse-
quences of four of these ‘non-canonical’ mutations in cultured neurons and mice to see if they reveal additional essential
domains without affecting known properties of MeCP2. The results show that the mutations partially or strongly deplete the
protein and also in some cases interfere with co-repressor recruitment. These mutations therefore impact the activity of
known functional domains and do not invoke new molecular causes of RTT. The finding that a stable C-terminal truncation
does not compromise MeCP2 function raises the possibility that small molecules which stabilize these mutant proteins may
be of therapeutic value.
Introduction
Mutations in the MECP2 gene cause the profound neurological
disorder Rett syndrome (1) (RTT, OMIM #312750). The gene prod-
uct, MeCP2 protein, is expressed in most cell types, but is espe-
cially abundant in neurons (2–4). Accordingly, loss of MeCP2
function has the most profound effect in the nervous system,
with minimal phenotypic consequences in other tissues (3,5,6).
Because of its association with intellectual disability in RTT and
other disorders, the MECP2 gene is frequently screened for
mutations in clinical cases of developmental delay. This has de-
fined many amino acid changes as RTT-causing or as relatively
benign or neutral variants that do not cause RTT (7,8). The
MeCP2 protein sequence is 95% identical between rodents and
humans, suggesting stringent purifying selection throughout.
Nevertheless, RTT missense mutations are non-randomly dis-
tributed in two prominent clusters, whereas apparently neutral
polymorphisms are broadly distributed across the remainder of
the protein (Fig. 1). The implication that RTT mutational
clusters mark critical domains is supported by biochemical
studies, which show that mutations within the Methyl-CpG
binding domain (MBD) disrupt DNA binding, whereas mutations
within the NCoR interaction domain (NID) prevent binding to
the NCoR/SMRT co-repressor complexes (9–11). High-resolution
X-ray crystallographic structures of both these interactions
support the view that MeCP2 bridges methylated sites on DNA
with a histone deacetylase-containing co-repressor (12,13).
Further evidence for the importance of these two domains
comes from a recent study in which mice carried a pared down
MeCP2 ‘minigene’, DNIC, consisting of only the MBD, a nuclear
localization signal and the NID (14). These mice survived for
over a year with only mild symptoms. A simple interpretation is
that this interaction restrains transcription; a view supported
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by recent transcriptomic analyses of MeCP2-depleted mouse
brain (15–17).
A significant limitation of this model for MeCP2 function is
that several recurrent mutations, whose causal role in RTT is
confirmed by their absence in both parents, lie outside the MBD
and NID (Fig. 1) and are absent in DNIC mice (14). Most promi-
nently, about 10% of all RTT cases involve a heterogeneous set
of small deletions in exon 4 of MECP2. The resulting frameshifts
introduce premature translational termination often preceded
by stretches of novel amino acid sequence of variable length
(18,19). As these C-terminal deletions (CTDs) are far down-
stream of the MBD and NID, they hint that there are other, as
yet undetected, functional domains within MeCP2. The same ar-
gument applies to two other recurrent RTT mutations, P225R
and P322L, which lie outside the minimal regions required for
DNA and NCoR binding. Here we use biochemical, cell biological
and genetic methods to show that these mutations recapitulate
RTT-like phenotypes in mice through either or both of two
mechanisms: 1) by destabilizing MeCP2, so that only a fraction
of the wild-type (WT) level remains; 2) by interfering with the
ability of MeCP2 to recruit the NCoR complex to chromatin and
repress transcription. Importantly, we find that one C-terminal
truncation is stable and functionally WT in a mouse sequence
context, but unstable and RTT-causing when the protein is
‘humanized’. This demonstrates that the truncation itself
only has a measurable functional consequence if it leads to de-
stabilization. From this and other data we conclude that these
‘non-canonical’ RTT mutations do not identify previously unap-
preciated functional domains. Moreover, our results highlight
the crucial role played by the MeCP2 protein sequence in ensur-
ing stability.
Results
P225R and P322L mutations cause Rett-like phenotypes
in mice
To test the hypothesis that the MBD and NID are key to MeCP2
function, we first identified RTT mutations that apparently
leave these domains intact. Next, we generated mouse models
to check that these recapitulated RTT-like phenotypes. Finally,
we used cellular and molecular assays to ask whether these
mutations affect the functions that have been attributed to the
MBD and the NID. According to our rationale, new functional
domains would be expected to cause RTT without compromis-
ing either binding to DNA or NCoR recruitment.
We initially selected the P225R and P322L mutations, which
occur in a relatively small number of RTT cases (Table 1).
Parental analysis has shown that these missense mutations
arise de novo in the affected individuals (7), strongly suggesting
that they are causative. We modeled these mutations by gene
targeting in mouse embryonic stem (ES) cells (Fig. 2a;
Supplementary Material, Fig. S1a) to produce mouse alleles that
differed from WT only at the patient mutation site and a single
loxP site remaining in intron 2 after deletion of the selection
cassette (Fig. 2a; Supplementary Material, Fig. S1b–e). To deter-
mine whether P225R and P322L cause RTT-like phenotypes in
mice, we injected mutant ES cells into blastocysts to create chi-
meras and bred them to establish Mecp2P225R (P225R) and
Mecp2P322L (P322L) mouse lines (Supplementary Material, Fig.
S2a and b). P322L hemizygous males appeared normal at wean-
ing, but from 5 weeks of age they developed RTT-like symp-
toms (20) that progressed rapidly (Fig. 2b), surviving to a median
age of 9 weeks (Fig. 2c). P322L males were also underweight
compared to littermate controls (Supplementary Material, Fig.
S3a). These mice were subjected to a program of behavioral
tests starting at 6 weeks old when the mutants were only mildly
symptomatic. They showed significantly decreased anxiety-like
behaviors in the elevated plus maze and open field test
(Supplementary Material, Fig. S3b and c) although their move-
ment was not significantly impaired (data not shown and
Supplementary Material, Fig. S3d). The wire suspension test and
accelerating rotarod (Supplementary Material, Fig. S3e and f) ex-
posed severe deficits in motor co-ordination and learning. Thus
P322L males exhibit a severe phenotype mimicking that of
Mecp2-null mice.
As with P322L mice, P225R males developed Rett-like symp-
toms at 6 weeks, but progression of symptoms was more grad-
ual (Fig. 2d). Median survival was 50 weeks (Fig. 2e). P225R
males were underweight compared to WT littermates
(Supplementary Material, Fig. S4a). Despite their extended sur-
vival time (the longest of any Rett mutation modeled in mice so
far), P225R mice showed a similar range of deficits to P322L in
behavioral tests. P225R males at 11 weeks of age appeared less
anxious than controls in the elevated plus maze and open field
test (Supplementary Material, Fig. S4b and c). They traveled a
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Figure 1. Population variants and RTT mutations in the coding sequence of MeCP2. A schematic diagram of human MeCP2 protein shows the methyl-binding domain
(MBD) and NCoR/SMRT interaction domain (NID). Single amino acid changes found in males in the ExAC exome sequence database are indicated above the protein and
RTT-causing mutations are shown below. Only male ExAC changes are shown to exclude the possibility that pathogenic mutations in females could be masked by
skewed X-inactivation. All RTT mutations have been shown to be absent in the parents in at least one case. Red box—range of deletion start points for C-terminal dele-
tion (CTD) RTT frameshift mutations. The ‘non-canonical’ RTT mutations that are the subject of this study are marked with asterisks.
2532 | Human Molecular Genetics, 2018, Vol. 27, No. 14
Downloaded from https://academic.oup.com/hmg/article-abstract/27/14/2531/4989385
by Edinburgh University user
on 07 August 2018
targeted
genomic locus
targeting
vector
Mecp2
genomic locus
1 2 3
30kb
4
loxP
3 4
plasmid subclone
loxP loxP
3 4
Neo Stop
*
RTT mutation
*
(a)
(b)
4 8 12 16 20 24
0
2
4
6
8
10
Age (weeks)
Ag
gr
eg
at
e 
Sc
or
e
P322L
WT
null
28
(c)
0 4 8 12 16 20 24 28
0
20
40
60
80
100
Age (weeks)
Pe
rc
en
t s
ur
viv
al
P322L
WT
null
(d)
4 8 12 16 20 24 28 32 36 40 44 48 52
0
2
4
6
8
10
Age (weeks)
Ag
gr
eg
at
e 
Sc
or
e
P225R
WT
flox
null
(e)
0 4 8 12 16 20 24 28 32 36 40 44 48 52
0
20
40
60
80
100
Age (weeks)
Pe
rc
en
t s
ur
viv
al
P225R
WT
null
Figure 2. P322L and P225R mutant mice show RTT-like phenotypes and a reduced lifespan. (a) The mouse Mecp2 genomic locus, the targeting vector used to make
P225R and P322L knock-in alleles in mouse ES cells, and the mutated genomic locus after Cre-mediated removal of the selection cassette. The region where the RTT
mutations were introduced is marked with an asterisk (*). (b) P322L hemizygous male mice show a rapid onset of RTT-like phenotypes. Mean aggregate phenotypic
score6SD plotted for each genotype, P322L n¼12 at 4 weeks, WT littermates n¼15. Representative Mecp2-null data are shown for comparison (n¼12 at 4 weeks). (c)
Kaplan–Meier survival plot for P322L hemizygous males and WT littermates shown in (b). (d) P225R hemizygous male mice also display RTT-like phenotypes. Mean ag-
gregate phenotypic score6SD plotted for each genotype, P225R n¼19 at 4 weeks, WT littermates n¼18. Representative Mecp2-null and Mecp2-flox data are shown for
comparison (flox n¼9). (e) Kaplan–Meier survival plot for P225R hemizygous males and WT littermates shown in (d).
Table 1. MECP2 mutations in this study. Amino acid and nucleotide locations are numbered according to the human e2 isoform. RettBASE fre-
quency is expressed as a percentage of all Rett syndrome cases with an MECP2 mutation
Mutation name Amino acid change Nucleotide change Mutation type RettBASE frequency MeCP2 domain
R111G R111G c.331 A>G RTT missense 0.03 MBD
P225A P225A c.673 C>G ExAC (male) n/a ID
P225R P225R c.674 C>G RTT missense 0.55 ID
R306C R306C c.916 C>T RTT missense 7.3 NID
P322L P322L c.965 C>T RTT missense 0.26 CTD
CTD1 L386HfsX5 c.1157–1197 D41 RTT del/frameshift 1.32 CTD
CTD2 P389X c.1164–1207 D44 RTT del/frameshift 1.29 CTD
MBD, methyl-CpG binding domain, ID, intervening domain (between the MBD and NID), NID, NCoR interacting domain and CTD, C-terminal domain.
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shorter distance in the open field (Supplementary Material, Fig.
S4d) and also demonstrated reduced motor co-ordination in the
wire suspension test (Supplementary Material, Fig. S4e), though
mutants did not perform less well than controls on the acceler-
ating rotarod (Supplementary Material, Fig. S4f). We conclude
that both P322L and P225R male mice show phenotypes
that overlap with those of other mouse models carrying Mecp2
mutations found in RTT (21–24).
P225R and P322L mutations differentially affect MeCP2
levels
To investigate the molecular basis of these RTT-like pheno-
types, we first measured MeCP2 abundance. Strikingly, the
amount of P322L protein in whole mouse brain was severely re-
duced (3% of WT littermates; Fig. 3a and b). Thus, despite WT
amounts of Mecp2P322L mRNA (Supplementary Material, Fig. S5a
and b), the level of P322L protein in brain is comparable to that
in Mecp2Stop/y mice, which also show a severe phenotype (22). In
P225R mouse brain, MeCP2 protein was at 22% of the WT level
(Fig. 3c and d), which is significantly more than in P322L
brain. The amount of Mecp2P225R mRNA was not affected
(Supplementary Material, Fig. S5b).
Reduced MeCP2 protein abundance was also observed in cul-
tured neurons derived from the mutant mouse ES cells (Fig. 3e–
g). Both P322L and P225R ES cells differentiated equally well into
neurons, as shown by NeuN expression (Fig. 3f) and displayed
equal amounts of Mecp2 mRNA (Supplementary Material, Fig.
S5c). However, protein levels in both mutants were significantly
lower than WT and WT þ lox controls (Fig. 3f and g).
Specifically, P225R showed a moderate reduction to around 60%
whereas P322L retained only 7% of the WT MeCP2 level.
P225R and P322L impair NCoR recruitment to chromatin
The drastic reduction in P322L MeCP2 explains the severe phe-
notype, but the P225R mutant is only partially depleted.
Notably, the level of P225R MeCP2 in whole brain is similar to
that of the hypomorphic floxed Mecp2 allele (6,25–27) (Fig. 3c),
which has a normal lifespan and much milder phenotypic pro-
gression than P225R (25–27) [data from (25) shown for compari-
son in Fig. 2d, yellow symbols]. The difference between
phenotypic outcomes may indicate that these two mouse lines
simply lie on either side of a threshold for functionally sufficient
MeCP2 protein levels. Alternatively, the P225R mutation may af-
fect MeCP2 function as well as abundance. To test the possibil-
ity that the residual mutant protein is functionally impaired, we
looked for other defects that might account for the RTT-like
phenotype. While many of the effects of MeCP2 mutations only
become apparent when studied in the context of the whole or-
ganism, some properties, such as recruitment of the NCoR/
SMRT co-repressor complex to chromatin, can be tested using a
simple transfection assay. P225R and P322L point mutations
were introduced into a WT mouse Mecp2 cDNA fused to the C-
terminus of enhanced green fluorescent protein (EGFP).
Interestingly, the Exome Aggregation Consortium (ExAC) data-
base identifies a hemizygous missense population variant also
at P225 (P225A) that presumably does not cause RTT. We in-
cluded this variant in our analysis and used Rett missense
mutations R306C and R111G as negative controls for NCoR and
chromatin binding, respectively (Table 1). When WT EGFP-
MeCP2 was expressed in mouse NIH-3T3 cells, green fluores-
cence co-localized with ‘DAPI bright spots’, which are
heterochromatic foci containing high concentrations of methyl-
ated DNA (28). A mutation that disrupts the MBD, R111G, abol-
ished binding of MeCP2 to methylated DNA and co-localization
was lost. Both P225R and P322L (in addition to controls P225A
and R306C) retained the ability to bind to heterochromatic foci,
indicating that MBD function is not affected in these mutants
(Fig. 4a).
MeCP2 interacts with the co-repressor complex NCoR/SMRT
via subunits TBL1X and TBL1XR1. This interaction is disrupted
by mutations in the NCoR/SMRT interaction domain, including
the common Rett mutation R306C. EGFP-tagged MeCP2 was
expressed in HEK 293 cells and immunoprecipitated from
150 mM salt extracts using GFP-Trap beads (Supplementary
Material, Fig. S6a). NCoR/SMRT components NCoR1, TBL1X and
HDAC3 co-immunoprecipitated with WT MeCP2 but not with
the R306C mutant or EGFP alone. Both P225R and P322L mutants
were able to immunoprecipitate the same NCoR/SMRT compo-
nents as the WT protein (Fig. 4b), showing that these mutations
do not impair the interaction of MeCP2 with the co-repressor
complex. The co-repressor mSin3a, which interacts relatively
weakly with MeCP2 (29), was immunoprecipitated by all mutant
MeCP2 proteins, including R306C (Supplementary Material, Fig.
S6b).
Although P225R and P322L can still interact with NCoR and
methylated DNA separately, we wished to know if they could
recruit the NCoR subunit TBL1X to heterochromatin, which
requires simultaneous binding to both macromolecules. To test
this, constructs expressing both EGFP-tagged MeCP2 and
mCherry-tagged TBL1X were transfected into mouse NIH-3T3
fibroblasts (Supplementary Material, Fig. S7a–e). It has been
shown previously (30) that TBL1X-mCherry, which lacks a nu-
clear localization signal, is normally excluded from the nucleus
(Supplementary Material, Fig. S7b), but in the presence of WT
EGFP-MeCP2 it is recruited to the methylation-rich 4’, 6-diami-
dino-2-phenylindole (DAPI) spots in 80% of doubly transfected
cells (Fig. 4c and d). As expected, the NID mutant R306C itself
localizes to the DAPI spots, but is unable to recruit TBL1X
(Fig. 4c). When P225R and P322L RTT mutants were tested in
this assay both showed impaired recruitment of TBL1X-
mCherry to DAPI spots in comparison with WT MeCP2. On the
other hand, the population variant P225A performed as well as
WT MeCP2 in this assay (Fig. 4d; Supplementary Material, Fig.
S7c). Thus the ability of both P225R and P322L to recruit NCoR/
SMRT to methylated sites in the genome is impaired. Though
performed in non-neuronal cells, this test appears to measure a
property of MeCP2 that is functionally relevant, as Rett muta-
tions register as defective. Strikingly, substitution of R at posi-
tion 225 causes RTT and prevents recruitment, whereas
substitution of A at the same site does not cause RTT and
recruits as efficiently as WT.
Failure to efficiently recruit the cognate co-repressor to
methylated sites in the genome suggested that P225R and P322L
might also be functionally defective in DNA methylation-
dependent transcriptional repression. To test this, untagged
MeCP2 was expressed in mouse tail fibroblasts that were com-
promised in their ability to repress methylated reporter genes
due to deletion of the genes for Mecp2 and Mbd2 as previously
described (6). The co-transfected reporter construct encoding
firefly luciferase was either unmethylated or methylated at ev-
ery CpG (Fig. 4e) and repression was expressed as the ratio of lu-
ciferase activities expressed by unmethylated versus
methylated constructs. Equivalent expression levels of WT,
R306C and P225R MeCP2 constructs were confirmed by western
blotting (Supplementary Material, Fig. S8a and b). Levels of
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P322L, however, were consistently low (30% of WT MeCP2;
data not shown), suggesting that lack of an EGFP tag rendered
the protein susceptible to degradation, as seen in neurons. As
the amount of MeCP2 directly correlates with the strength of re-
pression in this assay, we excluded the P322L mutant from the
transcriptional repression experiment. WT MeCP2 repressed the
methylated luciferase efficiently, whereas repression by P225R
was reduced by about half. The ability of R306C to repress was
about 25% that of WT MeCP2 in this assay (Fig. 4f). These find-
ings correspond well with the behavior of the mutants in the
TBL1X recruitment assay, where R306C was more severely af-
fected than P225R (and P322L), supporting the view that failure
to recruit the NCoR co-repressor underlies DNA methylation-
dependent transcriptional repression by MeCP2. It is possible
that the residual repression seen with R306C is due to recruit-
ment of another co-repressor, such as mSin3a, or to direct inter-
ference of dense methyl-CpG bound protein with the
transcriptional machinery.
C-terminal deletions do not affect MeCP2 function or
recruitment
Deletion-frameshift mutations in the C-terminal domain of
MECP2, generally between nucleotides c.1100 and c.1200 (human
e2 isoform numbering), are responsible for about 10% of all RTT
cases. We chose to model two of the most common confirmed
Rett-causing CTDs in mice: c.1157–1197 D41 (CTD1) and c.1164–
1207 D44 (CTD2; see Table 1). Native mouse MeCP2 contains a two
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Figure 3. P322L and P225R mutations result in decreased MeCP2 levels in mouse brain and in vitro differentiated neurons. (a) Western blot of whole brain lysates from
6-week-old P322L and WT littermate males. Mecp2-null and Mecp2-stop samples are shown for comparison. (b) Quantification of (a): the level of MeCP2 (MeCP2 signal/
H3 signal) as a percentage of mean WT is shown as mean (black line) and individual biological replicates (n¼3 animals). P¼0.0010 (**), two-tailed t-test with Welch’s cor-
rection for unequal variances. (c) Western blot of whole brain lysates from 9-week-old P225R and WT littermate males. Mecp2-null and Mecp2-flox samples are shown
for comparison. (d) Quantification of data shown in (c): the level of MeCP2 (MeCP2 signal/H3 signal) as a percentage of mean WT is shown as mean (black line) and indi-
vidual biological replicates (n¼3 animals). P¼0.0128 (*), two-tailed unpaired t-test with Welch’s correction for unequal variances. (e) Neuronal differentiation protocol
used to produce MeCP2-mutant neurons from mouse ES cells. EB: embryoid body, RA: retinoic acid, NP: neuronal precursor. (f) Representative western blot showing lev-
els of MeCP2 protein present in neurons on day 15 of the differentiation scheme. Lanes A and B for each genotype are derived from independently targeted ES cell
clones and WT pools are independent differentiations of the parental ES cell line. Histone H3 was used as a loading control for number of cells and NeuN as a control
for equal neuronal differentiation. (g) Quantification of MeCP2 levels in in vitro differentiated neurons. Two independent clones were differentiated two or three times
for each genotype. MeCP2 level (MeCP2 signal/H3 signal) is normalized to the mean WTþloxP value. Data shown as mean (black line) and individual values. n¼5 (WT
þloxP, P225R, P322L), n¼3 (WT pool) independent differentiations. Comparison to WTþloxP (two-tailed unpaired t-test with Welch’s correction for unequal variances):
P225R P¼0.0416 (*), P322L P¼0.0023 (***) and WT (pool) P¼0.4868 (ns).
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Figure 4. P225R and P322L show impaired NCoR/SMRT recruitment to methylated DNA. (a) WT and mutant EGFP-MeCP2 fusions expressed in mouse NIH-3T3 cells. (b)
Immunoprecipitation of EGFP-MeCP2 from transfected HEK 293 cells with GFP-Trap beads. NCoR/SMRT components NCoR1, TBL1X and HDAC3 detected in western
blots of input and immunoprecipitated samples. (c) TBL1X recruitment assay. Co-transfection of EGFP-MeCP2 and TBL1X-mCherry expression constructs into NIH-3T3
cells. WT EGFP-MeCP2, but not R306C, recruits TBL1X-mCherry to heterochromatic foci. Scale bar 10 lm. (d) Quantification of TBL1X recruitment efficiency of MeCP2
mutants. Percent of doubly transfected nuclei with TBL1X-mCherry/EGFP-MeCP2 spots from each independent transfection is shown as mean (black line) and individ-
ual values. n¼7 (WT), 4 (R306C, P322L), 3 (P225A, P225R) independent transfections. MeCP2 mutants were compared to WT using a two-tailed Mann–Whitney test.
R306C P¼0.0061 (**), P225A P¼0.1167 (ns), P225R P¼0.0167 (*), P322L P¼0.0061 (**). (e) Diagram of firefly luciferase expression construct pGL2-control consisting of an SV40
promoter, Luc coding sequence and SV40 polyadenylation signal and enhancer. The positions of CpG dinucleotides methylated by SssI.methylase are shown as black
lines. (f) Methylation-dependent transcriptional repression assay. Immortalized Mecp2/y, Mbd2/ mouse tail fibroblasts transfected with SssI-methylated or unmethy-
lated pGL2-control plasmid and an MeCP2 expression construct. Methylation-dependent repression expressed as the ratio of unmethylated/methylated (U/M) lucifer-
ase activity and normalized to WT for each transfection. For each genotype the mean (black line) and individual values for four (R306C) or six (no MeCP2, WT, P225R)
independent transfection experiments are shown. Each genotype compared to the WT value (100%) using a two-tailed one-sample t-test. No MeCP2 P<0.0001 (****),
R306C P<0.0001 (****), P225R P¼0.0002 (****).
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amino acid deletion relative to the human protein (Fig. 5a) that
coincides with the deletion hotspot in Rett patients. We modeled
these Rett mutations in the mouse genome by restoring the two
human-specific amino acids and by adding the patient missense
tail (CTD1: HQPPX, CTD2: X) (Fig. 5a). We first tested CTD1 and
CTD2 for methylated DNA-binding and NCoR/SMRT binding us-
ing transfection assays. Both were able to bind to methylated het-
erochromatic foci in transfected NIH-3T3 cells (Fig. 5b) and to co-
immunoprecipitate NCoR/SMRT components NCoR1, TBL1X and
HDAC3 (Fig. 5c) and mSin3a (Supplementary Material, Fig. S6b).
Moreover, unlike P225R and P322L, both CTD1 and CTD2 were
able to recruit TBL1X-mCherry to methylated heterochromatic
foci as efficiently as WT MeCP2 (Fig. 5d). Thus, neither of the trun-
cated proteins showed any deficiencies in MBD or NID function in
these assays.
CTD1 and CTD2 mutant phenotypes reflect MeCP2
protein level
The absence of overt defects in these assays raised the possibil-
ity that CTD1 and CTD2 disrupt other functional domains. To
explore this possibility, we used CTD1 and CTD2 targeting vec-
tors that retained all sequences downstream of the deletions to
create Mecp2CTD1/y and Mecp2CTD2/y ES cell lines (Supplementary
Material, Fig. S9a and b). After Cre-mediated deletion of the
floxed Neo-Stop selection cassette, the mutated Mecp2 alleles
differed from WT only at the mutation site and a loxP site up-
stream of exon 3. When these lines were differentiated into
neurons in vitro, both genotypes produced truncated MeCP2 pro-
tein as expected, but surprisingly the amount of protein differed
greatly. CTD1 retained only 3% the WT level, whereas the
amount of CTD2 MeCP2 was not significantly different from WT
controls (Fig. 5e and f). At the transcript level, CTD1 had only
34% WT mRNA whereas CTD2, like P225R and P322L, expressed
WT-levels of mRNA (Supplementary Material, Fig. S9c).
The extremely low level of MeCP2 protein in CTD1 neurons
predicted that mice would show a severe phenotype, similar to
P322L and Mecp2-null mice. To test this, we produced CTD1 mice
using CRISPR/Cas9 cutting and repair with an oligonucleotide
template in mouse zygotes. After confirming the presence of the
mutation by sequencing (data not shown) and southern blot
(Supplementary Material, Fig. S10a and b), analysis of CTD1
founder males showed that the amount of MeCP2 in whole brain
was reduced to about 10% of that in WT controls (Fig. 6a and b)
and the mRNA to 45% of WT (Supplementary Material, Fig. S10e).
A cohort of CTD1 male mice was scored for Rett-like phenotypes,
which progressed rapidly (Fig. 6c), giving a median survival of 20
weeks (Fig. 6d). The weights of CTD1 mice were not significantly
different to those of WT littermates (Supplementary Material, Fig.
S10c). This cohort was still on a mixed CBA/C57BL6 genetic back-
ground whereas small size is usually seen in Mecp2-mutant males
on a more inbred C57BL6 background.
The instability of CTD1 made it impossible to deduce
whether the C-terminal truncation mutation gave rise to a novel
functional defect in MeCP2 as at 10% of WT littermate controls
the level of protein was similar to the level of full-length protein
in Mecp2Stop/y mice, which resemble Mecp2-null mice (22). On the
other hand, the fully stable CTD2 mutant protein offered the
chance to test the importance of this C-terminal region. CTD2
mice were therefore produced using standard injection of ES
cells into mouse blastocysts and verified by southern blots
(Supplementary Material, Fig. S10d) and sequencing (data not
shown). As in cultured neurons, CTD2 MeCP2 protein and
mRNA levels in whole brain were not significantly different
from WT littermate controls (Fig. 6a and b; Supplementary
Material, Fig. S10e). Strikingly, CTD2 male hemizygous mice and
WT littermate controls were phenotypically indistinguishable
over the course of 1 year (Fig. 6e and f). Survival was 100% and
CTD2 mice behaved as WT in the elevated plus maze (Fig. 6g),
open field test (Fig. 6h; Supplementary Material, Fig. S10f) and
accelerating rotarod (Fig. 6i). In the wire suspension test CTD2
mice performed significantly better than WT littermates
(Supplementary Material, Fig. S10g). We conclude that the CTD2
C-terminal truncation of MeCP2 has no overt phenotypic conse-
quences in this mouse model and therefore does not identify a
previously unknown functional domain.
‘Humanization’ of the CTD2 allele reduces protein levels
in neurons
All Rett mutations previously studied in mice have replicated
the disease seen in patients, including the relative severity of
symptoms (5,6,23,24,31–33). Why should CTD2 be exceptional?
A potential explanation was that subtle differences in amino
acid sequence between human and mouse MeCP2 proteins
were involved. Despite 95% identity of MeCP2 protein between
the two species, several amino acid differences persisted near
the truncated region (Fig. 7a). To test whether these differences
altered stability of the mutant, we created a ‘humanized’ CTD2
allele (CTD2hu) in mouse ES cells by making three single nucle-
otide alterations: T376P, M380V and S387P (Fig. 7a). These
changes ensure that the amino acid sequence of the C-terminus
of MeCP2 in patient and mouse alleles is identical from E298,
which is N-terminal to the NID, to the stop codon. CTD2hu ES
cell clones were produced (Supplementary Material, Fig. S11a
and b) and differentiated into neurons for comparison with
CTD1, CTD2 and WT þ lox controls. Western blots showed a
dramatic destabilization of CTD2hu, which was now indistin-
guishable from CTD1 (7.4 and 5.0% WT þ lox, respectively,
Fig. 7b and c). The original CTD2 MeCP2 protein remained essen-
tially identical to WT þ lox controls (93%). CTD2hu neurons also
contained less mRNA than WT þ lox and CTD2, again resem-
bling CTD1 (Supplementary Material, Fig. S11c). Thus, altering
the sequence context of the non-pathogenic CTD2 mouse allele
to make it resemble the patient mutation more closely resulted
in a drastic reduction in the amount of MeCP2 in neurons.
To further confirm our hypothesis that CTD2 MeCP2 is unsta-
ble in human neurons we created a knock-in MECP2CTD2 allele in
Lund human mesencephalic cells (LUHMES) cells, a human neuro-
nal progenitor cell line derived from human embryonic ventral
mesencephalic tissue which can be differentiated in vitro to pro-
duce a uniform population of mature dopaminergic neurons
(34,35). Knock-in clones containing MECP2CTD2 alleles on the active
X chromosome, and thus expressing MeCP2 CTD2 protein, were
produced using CRISPR/Cas9 cutting and an oligodeoxynucleotide
repair template as previously described (35) (Supplementary
Material, Fig. S11d and e). After differentiating for 9 days to mature
neurons, the level of CTD2 MeCP2 protein was severely reduced
compared to the WT parental cells and unmodified WT clones
(Fig. 7d and e). MeCP2 protein levels in CTD2 clones ranged from 7
to 20% of the parental WT cells. These findings in mice, mouse ES
cell-derived neurons and human neurons strongly suggest that
RTT resulting from CTD mutations is due to severe MeCP2 defi-
ciency rather than the loss of essential domains in the C-terminal
region.
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Figure 5. C-terminal truncation mutants CTD1 and CTD2 show normal NCoR/SMRT recruitment but differ in neuronal protein levels. (a) Comparison of the human and
mouse MeCP2 CTD regions for wild-type (WT) and the patient mutations CTD1 and CTD2. Amino acid changes and absent amino acids in the mouse protein are shown
in red, amino acids added to mouse CTD1 and CTD2 proteins in blue and missense/nonsense changes arising due to deletion/frameshift in bold type. (b) WT, CTD1 and
CTD2 EGFP-MeCP2 fusions expressed in mouse NIH-3T3 cells. (c) Immunoprecipitation of EGFP-MeCP2 from transfected HEK 293 cells with GFP-Trap beads. NCoR/
SMRT components NCoR1, TBL1X and HDAC3 detected in western blots of input and immunoprecipitated samples. (d) Quantification of TBL1X recruitment efficiency
of MeCP2 mutants. Percent of doubly transfected nuclei with TBL1X-mCherry/EGFP-MeCP2 spots in each independent transfection shown as mean (black line) and in-
dividual values. WT n¼7, R306C, CTD1, CTD2 n¼4 independent transfections. Genotypes were compared to WT using a two-tailed Mann–Whitney test. R306C P¼0.0061
(**), CTD1 P¼0.0727 (ns), CTD2 P¼0.6485 (ns). (e) Representative western blot showing levels of MeCP2 protein present in neurons on day 15 of differentiation (7 days af-
ter plating). Lanes A and B for each genotype are derived from independently targeted ES cell clones and WT pools are independent differentiations of the parental ES
cell line. An antibody against the N-terminus of MeCP2 detects both full-length and truncated (D) protein. (f) Quantification of MeCP2 levels in in vitro differentiated
neurons. Two independent clones were differentiated 2 or 3 times for each genotype. MeCP2 level (MeCP2 signal/H3 signal) is normalized to the mean WTþ loxP value.
Data shown are mean (black line) and five (WTþloxP, CTD1) or three (CTD2, WT pools) independent differentiations. Comparison to WTþloxP (two-tailed unpaired
t-test with Welch’s correction for unequal variances): CTD1 P¼0.0021 (***), CTD2 P¼0.1874 (ns) and WT (pool) P¼0.4868 (ns).
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Discussion
Biochemical and cell biological studies of MeCP2 have identified
numerous interacting proteins that potentially mediate its
function. So far, only two of these are implicated in RTT, as
causal missense mutations disrupt the interactions with meth-
ylated DNA or with the NCoR/SMRT co-repressor complexes
(11). We were intrigued by a number of RTT mutations that
leave the MBD and the NID intact, and by the possibility that
they might direct us to additional functional domains that had
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Figure 6. CTD1 and CTD2 mice show contrasting phenotypes due to different levels of MeCP2 in brain. (a) Western blot of whole brain lysates from 6-week-old CTD1,
CTD2 and WT males. A Mecp2-null sample is shown for comparison. CTD1 and CTD2 mice express a truncated protein, MeCP2D. (b) Quantification of (a): the level of
MeCP2 (MeCP2 signal/H3 signal) as a percentage of mean WT shown as mean (black line) and individual values for each genotype (n¼3 animals). Comparison to WT
(two-tailed unpaired t-test with Welch’s correction for unequal variances): CTD1 P¼0.0008 (***) and CTD2 P¼ 0.1773 (ns). (c) CTD1 hemizygous males display RTT-like
phenotypes. Mean aggregate phenotypic score6SD plotted for mutants and WT male littermates, CTD1 n¼11, WT n¼7 (at 4 weeks). (d) Kaplan–Meier survival plot for
CTD1 hemizygous males and WT littermates shown in (c). (e) Phenotypic scoring of CTD2 males and WT littermates. Mean aggregate phenotypic score6SD plotted for
mutants and WT male littermates, CTD2 n¼16, WT n¼17. (f) Mean weight6SD for animals shown in (e). (g) Elevated plus maze. Percentage of time spent in the closed
and open arms is shown as mean (black line) and individual values. Percentage time in open and closed arms for each genotype was compared using two-tailed un-
paired t-tests: closed arms P¼0.2238 (ns), open arms P¼0.3713 (ns). (h) The ratio of distance travelled in the central zone of the open field arena to total distance trav-
elled shown as mean (black line) and individual values. Two-tailed unpaired t-test test P¼0.9394 (ns). (i) Accelerating rotarod test. The latency to fall is shown as mean
(black line) and individual data points on each day. Two-way ANOVA (repeated measures) [genotype effect, F(1, 17)¼9.451106, P¼ 0.9976 (ns)]. (g)–(i) CTD2 n¼9, WT
n¼10.
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previously escaped detection. To be certain that the mutations
are genuinely causative of the disorder, we confined our atten-
tion to variants shown to be absent in parental DNA. The impor-
tance of this criterion is illustrated by E397K, which has been
detected several times in classical RTT (7), but has subsequently
been classified as a relatively common and phenotypically be-
nign population variant (7,8). By studying C-terminal trunca-
tions and the missense mutations P225R and P322L, which are
(a)
(b) (c)
(e)(d)
Figure 7. A humanized CTD2 allele expresses low levels of truncated MeCP2. (a) The amino acid sequences of the extreme C-termini of CTD1, CTD2 and CTD2hu mouse
alleles and their corresponding human RTT alleles. Missense/nonsense changes caused by the deletion-frameshift are in bold type. Residues where the mouse allele
differs from human are shown in red. Changes between CTD2 and CTD2hu are underlined. (b) Western blot showing levels of MeCP2 protein present in neurons on day
15 of differentiation (7 days after plating). Lanes A, B (and C) for each genotype are derived from independent mouse ES cell clones. An antibody against the N-terminus
of MeCP2 detects both full-length and truncated (D) protein. (c) Quantification of MeCP2 levels in in vitro differentiated neurons. Two or three independent clones were
differentiated for each genotype. MeCP2 level (MeCP2 signal/H3 signal) is normalized to the mean WTþloxP value. Data shown are mean (black line) and individual val-
ues for three (WTþloxP, CTD2hu) or two (CTD1, CTD2) independent differentiations. Comparison to WTþloxP (two-tailed unpaired t-test with Welch’s correction for
unequal variances): CTD1 P¼0.0108 (*), CTD2 P¼0.5450 (ns) and CTD2hu P¼0.0111 (*). (d) Western blot showing levels of MeCP2 protein present in LUHMES-derived hu-
man neurons on day 9 after precursor plating. Differentiations of one MECP2-null clone, two WT pools, two unmodified WT clones and three CTD2 LUHMES clones are
shown. An antibody against the N-terminus of MeCP2 detects both full-length and truncated (D) protein. (e) Quantification of MeCP2 levels in LUHMES-derived neurons.
Three independent differentiations were performed for each of the clones shown in (d). MeCP2 level (MeCP2 signal/H3 signal) is normalized to the WT pool value for
each differentiation. Data shown are mean (black line) and individual values for three independent differentiations. Comparison to WT A (two-tailed unpaired t-test):
WT B P¼0.0798 (ns), CTD2 A P¼0.0015 (***), CTD2 B P¼0.0039 (***), CTD2 C P¼0.0027 (***).
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recurrent RTT mutations remote from the two known interac-
tion sites, we failed to establish new functional domains of
MeCP2. Instead, our results can provide coherent molecular
explanations for the deleterious effects of these mutations by
considering MeCP2 as a recruiter of histone deacetylase com-
plexes to chromatin (29). Further evidence that it is the confor-
mation and/or stability of MeCP2 that is affected by these
mutations rather than functional domains containing P225,
P322 or the CTD region comes from a severely truncated mouse
knock-in allele, DNIC, which despite lacking all of these sites
shows a very mild phenotype, distinct from that seen in RTT
mouse models (14).
It is clear from studies of patient severity (18,33,36,37) and
mouse models (5,6,24,31) that mutations in the MBD and the
NID, such as T158M and R306C, are somewhat less severe on av-
erage than complete absence of the protein. This suggests that
these mutant proteins retain some function, which could come
from a number of sources. T158M does not completely abolish
binding to methylated DNA (24) and some residual binding of
R306C to NCoR components can be seen in this study (Fig. 4b;
Supplementary Material, Fig. S6b). All MeCP2 proteins tested
could bind to mSin3a (Supplementary Material, Fig. S6b). It has
been proposed that other domains such as AT-hooks (38,39)
may also contribute low-level function of MeCP2 when the MBD
and NID are mutated.
P225R leads to moderate destabilization of MeCP2, but it also
interferes with its ability to recruit the co-repressor subunit
TBL1X to chromatin and to impose DNA methylation-
dependent transcriptional repression. Although P225 is in an
unstructured region of the protein, it has been reported that
conformational changes occur on binding to DNA (40). P225R
may hinder the ability of MeCP2 to form the required bridge be-
tween chromatin and co-repressor complex. It is also possible
that the same conformational change leads to instability of the
protein. The combination of these two partial defects in stability
and function can explain the moderate RTT-like phenotype of
these mice. Importantly, a rare human population variant at the
same amino acid, P225A, does not interfere with co-repressor
recruitment. The strong correlation between the ability to re-
cruit co-repressor to methylated DNA and phenotypes in mice
and humans strengthens the notion that this is a key role of
MeCP2.
The other non-canonical missense mutation, P322L, severely
destabilizes MeCP2 and this alone can account for the resulting
severe phenotype. The C-terminal truncations CTD1 and
CTD2hu also severely destabilize the protein in neurons, but do
not detectably compromise several aspects of its function in cell
transfection-based assays. Emphasizing this point, CTD2 mice,
which lack 100 amino acids from the C-terminal end of MeCP2,
are viable, fertile and phenotypically normal in a series of be-
havioral assays. We note that this truncation removes an
activity-dependent phosphorylation site at S421 (S423 in human
MeCP2) that has previously been implicated in neuronal func-
tion, including dendritic patterning and spine morphogenesis
(41–44). The region has also been implicated in regulation of
micro-RNA processing and dendritic growth (45). Although loss
of these functional domains evidently does not make a detect-
able contribution to the major RTT-like phenotypes in mice, we
cannot exclude the possibility that subtle phenotypic conse-
quences were not detected by our assays or that they are impor-
tant for higher functions present in humans but not in mice.
MeCP2 instability has previously been noted as a result of
mutations that also disrupt the functional domains of MeCP2,
including missense mutations T158A (31), T158M and R133C (24)
and nonsense mutations R168X (23) and R255X (32). Our results
show that MeCP2 deficiency due to protein destabilization alone
is a major underlying cause of RTT. Although we only tested
two CTD mutations, we suggest that severe MeCP2 destabiliza-
tion is a mechanism that applies generally to this RTT mutation
category. Why mutations outside the key functional domains
should confer instability is unknown. With the exception of the
MBD and NID domains, whose 3D conformation has been deter-
mined (12,13), most of the protein is thought to be unstructured
(40). Surprisingly, the instability of CTD2 in the context of hu-
man MeCP2 was suppressed by changing three nearby amino
acids to match the mouse MeCP2 sequence. This serendipi-
tously allowed us to determine that the deletion of the MeCP2
CTD beyond amino acid 388, thereby losing 100 amino acids
from the C-terminus, has no deleterious phenotypic consequen-
ces. We conclude therefore that this mutation does not identify
a novel functional domain, but causes RTT in humans purely
due to drastic destabilization of the protein.
The dramatic difference in the stability of CTD2 conferred by
human versus mouse sequences indicates that subtle changes
in protein primary structure can have dramatic consequences
for MeCP2 abundance. It is also interesting that CTD alleles that
result in reduced protein levels also have less mRNA, although
the decrease is less severe. Further investigation of the precise
cause of CTD instability will be a focus of future research.
Importantly, the finding that CTD mutations do not appear to
affect MeCP2 function may offer therapeutic opportunities. A re-
cent study has demonstrated the use of proteasome inhibitors
to increase the level of unstable T158M MeCP2 (46).
Alternatively, small molecules that bind to the mutant CTD and
affect its conformation may improve stability and therefore pro-
vide clinical benefit.
Materials and Methods
Mecp2mutant mouse alleles
RTT mutations P225R, P322L, CTD1, CTD2 and CTD2hu were in-
troduced into a targeting vector (20) (Fig. 2a) containing WT
Mecp2 sequences and a Cre-excisable selection cassette using
the QuikChangeII XL Site-Directed Mutagenesis kit (Agilent
Technologies). Targeting vectors were linearized at the 30 end
using NotI and electroporated into 129/Ola E14Tg2a mouse ES
cells (a gift from A. Smith, University of Edinburgh). Correctly
targeted clones were identified by an initial PCR screen:
forward primer: 50-TCACCATAACCAGCCTGCTCGC-30
reverse primer: 50-ATTCGATGACCTCGAGGATCCG-30)
followed by Southern blotting of candidate clones and sequenc-
ing of the mutation sites (Supplementary Material, Figs S1 and
S9). A number of clones that had recombined to include the
floxed selection cassette but no RTT mutation were also verified
for use as controls (WT þ lox).
Differentiation of ES cells into neurons
ES clones were transiently transfected with a pCAGGS-Cre ex-
pression plasmid and clones that had deleted the Neo selection
cassette were verified by PCR, Southern blotting and sequencing
before differentiation into neurons. Two independently targeted
clones were used for each genotype, and each clone was differ-
entiated into neurons two or three times. Differentiation was
carried out using a 4-/4þ retinoic acid (RA) procedure as previ-
ously described (47,48). Neural precursor cells were seeded onto
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6 cm dishes at a density of 1.5105 cells/cm2 and harvested after
7 days by scraping into phosphate-buffered saline (PBS), pellet-
ing the cells and snap freezing.
Generation of CTD2 LUHMES cell lines
The LUHMES cell line (ATTC CRL-2927) was obtained from ATCC
and cultured according to the methods described in Scholz et al.
(49), with some minor alterations. All vessels were coated in
poly-L-ornithine and fibronectin overnight at 37C. Proliferating
LUHMES cells were seeded at 2106 cells/T75 flask every 2 days.
For differentiation, 2.5106 cells were seeded in a T75 flask for
the first 2 days of the protocol and on day 2 cells were seeded at
6106cells/10 cm dish. During differentiation a half-media
change was performed on day 6 and neurons were harvested
for protein on day 9.
To introduce a CTD2 knock-in mutation, LUHMES cells were
transfected with plasmid pSpCas9(BB)-2A-GFP (pX458) (a gift
from Feng Zhang, Addgene plasmid #48138) containing the
sgRNA sequence 50-TCCTCGGAGCTCTCGGGCTC-30, and single-
stranded oligodeoxynucleotide 50CCATCACCACCACTCAGAGTC
CCCAAAGGCCCCCGTGCCACTGCTCCCACCCCTGCCGCCCTGAGC
CCCAGGACTTGAGCAGCAGCGTCTGCAAAGAGGAGAAGATGCCC
AGAGGAGGCT30 (Sigma, desalted). Cells were transfected by
Nucleofection (Lonza) using a Basic Nucleofector kit for primary
neurons (VAPI-1003) and a Nucleofector II device, and fluores-
cence activated cell sorting (FACS)-sorted to isolate clones as
previously described (35).
LUHMES clones were analyzed by sequencing of genomic
DNA and cDNA and by Southern blotting (Supplementary
Material, Fig. S11d and e) to isolate clones that were either ho-
mozygous for the CTD2 mutation, or heterozygous and express-
ing the CTD2 mutation from the active X-chromosome
(LUHMES cells are female, XX). Three CTD2 clones (two homozy-
gous and one heterozygous) and two unmodified WT control
clones were used for further analysis.
LUHMES clones were differentiated to mature neurons as
previously described (49). A null clone (H4) was described previ-
ously (35). All clones and the parental cell line underwent three
independent differentiations and were harvested on day 9 of
differentiation by scraping into PBS, pelleting the cells and snap
freezing.
Establishment ofMecp2mutant mouse lines
P225R, P322L and CTD2 mouse lines were generated by injection
of ES cells into mouse blastocysts using standard methods.
Chimeric males were crossed with CMVCre deleter females (50)
to remove the selection cassette. This and subsequent genera-
tions were bred by crossing Mecp2-mutant heterozygote females
with C57BL/6J WT males. The genotypes of mutant lines were
confirmed by Southern blotting (Supplementary Material, Figs
S2a and b and S10d) and sequencing. Routine genotyping was
performed by PCR across the loxP ‘scar’ site remaining in the
mutant alleles after selection cassette removal (forward primer:
p5 50-TGGTAAAGACCCATGTGACCCAAG-30, reverse primer:
p7 50-GGCTTGCCACATGACAAGAC-30, WT 416bp, WT þ loxP
558bp).
The CTD1 mouse line was created by pronuclear injection of
Cas9 protein (Integrated DNA Technology), synthetic tracrRNA
and crRNA (target sequence ACCTGAGCCTGAGAGCTCTG)
(Sigma) and an oligonucleotide repair template (GCACCATCATC
ACCACCATCACTCAGAGTCCACAAAGGCCCCCA
TGCCACTGCTCCCACCCCACCAGCCCCCCTGAGCCTCAGGACTTG
AGCAGCAGCATCTGCAAAGAAGAGAAGATGC) (Sigma) into
C57BL6/J: CBA/CaOlaHsd F2 fertilized oocytes as previously de-
scribed (51). Correctly mutated founder animals were identified
by sequencing across the deletion site. One CTD1 hemizygous
male founder was able to breed and female heterozygous off-
spring were checked by sequencing and Southern blot
(Supplementary Material, Fig. S10a and b) and used for further
breeding of the line.
Phenotypic analysis
Cohorts of hemizygous mutant male mice and WT littermates
were weighed and scored weekly for a range of RTT-like pheno-
types to give an aggregate score between 0 and 12 as previously
described (20,25). Cohorts of at least eight mutants and eight
WT littermates were scored for each genotype, with higher
numbers being used where available to allow for any losses
unrelated to the mutation, such as fighting. Scoring was carried
out blind to genotype and to previous scores. Animals that
scored a maximum score of 2 for tremor, breathing or general
condition or which had lost 20% of their body weight had
reached the severity limit of the experiment according to the
Home Office license and were humanely culled. These animals
were counted as having ‘died’ for the purposes of survival data.
Animals of any genotype which were culled for reasons not
linked to the mutation, such as fighting with cage mates, were
removed from survival plots at that point (censored data).
P225R, P322L and CTD2 animals had been backcrossed to
C57BL6/J for three generations and CTD1 animals only once.
Behavioral testing was carried out on cohorts of mice that
had been backcrossed to C57BL6/J for four generations. Testing
took place over a 9-day period in the order: day 1: elevated plus
maze (115 min trial), day 2: open field test (120 min trial), day
3: wire suspension test (3 trials of 30 sec separated by 15 min),
day 6: accelerating rotarod habituation (5 min at 4 rpm), days 7–
9: accelerating rotarod trials (4 trials per day separated by 1 h).
Tests were performed as previously described (24,25).
Hemizygous male mutant mice and WT littermates were tested
at an age appropriate to the development of symptoms for that
line: testing was started for P322L at 6 weeks, P225R 11 weeks
and CTD2 18 weeks. A cohort size of 10 animals per genotype
was chosen as the largest number of animals that could reason-
ably be tested in a single session. Mice were housed in mixed
mutant and WT littermate groups. Mice were tested blind to ge-
notype and in order of ID number, giving a random order of mu-
tant and WT animals. Positions on the rotarod were assigned to
ensure equal representation of mutant and control animals at
each of the five positions.
RNA preparation and qRT-PCR
Total cellular RNA was prepared from in vitro differentiated neu-
rons (7 days after plating, 107 cells) and mouse brain (half brain)
using TriReagent (Sigma). cDNA was prepared using a
QuantiTect kit (Qiagen) and amplified in a qPCR reaction using
SensiMix SYBR and Fluoroscein Master Mix (Bioline) using pri-
mers for Mecp2 (forward: 50-ACCTTGCCTGAAGGTTGGAC-30, re-
verse: 50-GCAATCAATTCTACTTTAGAGCGAAAA-30) and control
Cyclophilin A (forward: 50-TCGAGCTCTGAGCACTGGAG-30, re-
verse: 50-CATTATGGCGTGTAAAGTCACCA-30). Samples were
run in triplicate and the amount of Mecp2 cDNA calculated for
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each biological replicate using the ‘double delta’ method after
correction of CT values using a standard curve.
Protein extracts and western blotting
In vitro differentiated ES cell-derived and LUHMES-derived neu-
rons and whole brain samples were prepared for western blot-
ting as previously described (3). Extracts were run on TGX 4–20%
gradient gels (BioRad) loading extract equivalent to 5  105 nu-
clei per well. Samples were run on duplicate gels and trans-
ferred to nitrocellulose membrane overnight in the cold at 25 V.
Western blots were processed as described previously (3) using
the following antibodies: anti-MeCP2 (N-terminus): mouse
monoclonal Men-8 (Sigma), anti-NeuN: rabbit polyclonal ABN78
(Millipore) and anti-histone H3: rabbit polyclonal ab1791
(Abcam). Western blots were developed with IR-dye secondary
antibodies (IRDye 800CW donkey anti-mouse, IRDye 680LT don-
key anti-rabbit, LI-COR Biosciences) and scanned using a LI-COR
Odyssey machine. Images were quantified using Image Studio
Lite software (LI-COR Biosciences). The ratio of NeuN: histone
H3 signals for each lane was used to check for equal neuronal
in vitro differentiation and clones that did not differentiate well
were discarded. MeCP2 levels were normalized to the histone
H3 signal for each lane to compare the amount of MeCP2/nu-
cleus between samples.
EGFP-tagged cDNA constructs and transfection assays
Mouse Mecp2 cDNA (e2 isoform) was cloned into the vector
pEGFP-C1 (Clontech) to create in-frame fusions with an N-termi-
nal EGFP tag. Missense mutations were introduced using the
QuikChangeII XL Site-Directed Mutagenesis kit (Agilent
Technologies) and truncations by PCR amplifying the cDNA
with a modified reverse primer before cloning into the expres-
sion vector. A vector expressing mCherry-tagged mouse TBL1X
was described previously (30). For localization of EGFP-MeCP2
and co-localization of EGFP-MeCP2/TBL1X-mCherry constructs
were transfected into NIH-3T3 mouse fibroblasts (93061524,
ECACC) growing on glass coverslips using Lipofectamine
(Thermo Fisher). Cells were fixed in 4% paraformaldehyde 48 h
after transfection, stained with DAPI and mounted in ProLong
Diamond mountant (Thermo Fisher). Images were captured us-
ing a Leica SP5 confocal microscope with 63 objective. For
western blotting to test expression levels of EGFP-MeCP2 WT
and mutant proteins cells were transfected with EGFP-MeCP2
and TBL1X-mCherry expression constructs as above and har-
vested 48 h after transfection by trypsinization. Cell pellets
were prepared for western blotting as described above for
in vitro differentiated neurons. MeCP2 was detected using
mouse monoclonal Men-8 (Sigma) and anti-c-tubulin mouse
monoclonal GTU-88 (Sigma) was used as a loading control.
For quantification of TBL1X-mCherry co-localization with
EGFP-MeCP2, 3–7 independent transfections were performed for
each genotype, with each transfection experiment including
EGFP-MeCP2 WT (positive control) and EGFP-MeCP2 R306C (neg-
ative control). Fields of cells were selected for scoring based on
the presence of an EGFP (MeCP2) signal in at least one cell in the
field, without observing the mCherry channel. Cells with both
EGFP and mCherry fluorescence were then scored for the pres-
ence or absence of TBL1X-mCherry spots in the nucleus, co-lo-
calized with EGFP-MeCP2 and the DAPI bright spots. In each
transfection at least 15 cells on 4 coverslips (total 60 cells per ge-
notype) were counted, blind to the genotype. The percentage of
double-transfected cells with DAPI/EGFP/mCherry co-localized
spots was then calculated for each genotype in each indepen-
dent transfection.
Co-immunoprecipitation assay
EGFP-MeCP2 expression constructs were transfected into HEK
293FT cells (R70007, ThermoFisher) using Lipofectamine and
cell pellets were harvested 24 h after transfection and snap fro-
zen. Cell pellets were treated with Benzonase (Sigma) in low salt
NE1 buffer (20 mM HEPES pH7.5, 10 mM NaCl, 1 mM MgCl2, 0.1%
Triton-X100, 10 mM b-mercaptoethanol and protease inhibitors)
to release chromatin bound proteins and then extracted with
150 mM NaCl. Supernatant extracts were mixed with GFP-
TrapVR _A beads (Chromotek) and after washing beads were
boiled in SDS-PAGE sample buffer and released proteins and in-
put extract samples run on 4–15% TGX gradient gels (BioRad)
and blotted as above. Co-immunoprecipitated proteins were
detected with the following antibodies: anti-NCoR: rabbit poly-
clonal A301–145A (Bethyl Laboratories), anti-TBL1X: rabbit poly-
clonal ab24548 (Abcam), anti-HDAC3: mouse monoclonal 3E11
(Sigma), anti-mSin3a: rabbit polyclonal ab3479 (Abcam) and
anti-EGFP: mouse monoclonal Living Colors JL-8 (Clontech).
Methylation-dependent repression assay
WT and mutant mouse Mecp2 e1 cDNAs were cloned into the
expression vector pcDNA3.1(þ) IRES GFP, a gift from Kathleen L
Collins, Addgene plasmid #51406 (52). The methylation-
dependent repression assay was performed as previously de-
scribed (6) by co-transfecting MeCP2 expression plasmid, Firefly
luciferase (Luc) construct pGL2-control (with or without SssI
methylation) and Renilla luciferase (Ren) transfection control
plasmid into a Mecp2/y, Mbd2/ mouse tail fibroblast cell line
(6) using Lipofectamine. Luciferase signal was measured using
the Dual Luciferase Assay kit (Promega). The ratio Luc/Ren sig-
nal was calculated for each well and the mean unmethylated:
mean methylated (U/M) value calculated for each genotype.
Each combination was repeated in triplicate in each experiment
and each MeCP2 genotype was independently transfected at
least four times. To check for equal expression of MeCP2 pro-
tein, total protein extract from triplicate wells transfected with
either unmethylated or methylated luciferase template and
each of the MeCP2 expression constructs was western blotted
and the level of MeCP2 (normalized to c-tubulin) determined.
Primary antibodies: anti-MeCP2 rabbit monoclonal D4F3 (Cell
Signaling Technology) and anti-c-tubulin mouse monoclonal
GTU-88 (Sigma).
Statistical Analysis
All statistical analysis was performed using GraphPad Prism
(GraphPad Software). Datasets were compared using Student’s
t-tests (with or without Welch’s correction for unequal variance,
as appropriate), apart from the TBL1X-mCherry co-localization
assay and wire suspension test that were analyzed using a non-
parametric Mann–Whitney test due to the nature of the data.
Rotarod data were tested using two-way repeated measures
ANOVA, followed by post-hoc testing for significance on each
day using the Holm–Sidak method.
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